184 results on '"Peters, Anju T."'
Search Results
2. The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps
3. Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)
4. 1237. Inpatients with a beta-lactam antibiotic allergy label (BAAL) and unrevealed tolerance: A prevalence study aimed to prioritize non-invasive delabeling for antimicrobial stewardship programs
5. Impact of dupilumab across seasons in patients with type 2 uncontrolled, moderate-to-severe asthma
6. BASELINE CHARACTERISTICS OF PATIENTS WITH MODERATE-TO-SEVERE ASTHMA WITH AND WITHOUT COEXISTING ATOPIC DERMATITIS PARTICIPATING IN THE RAPID REGISTRY STUDY
7. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52
8. Evaluation and treatment of rhinosinusitis with primary antibody deficiency in adults: Evidence‐based review with recommendations
9. Sinus inflammation and chronic rhinosinusitis are associated with a diagnosis of new onset asthma in the following year
10. The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics
11. Risk of new onset and prevalent disease in chronic rhinosinusitis: a prospective cohort study
12. Rhinitis and rhinosinusitis
13. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis
14. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps
15. Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps
16. Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis
17. Management and referral patterns for new-onset chronic cough in primary care patients
18. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
19. CHARACTERIZATION OF PATIENTS WITH ASTHMA TREATED WITH DUPILUMAB IN A REAL-WORLD SETTING: THE RAPID REGISTRY
20. Clinical and economic burden of chronic rhinosinusitis with nasal polyposis: A U.S. administrative claims analysis
21. Strong and consistent associations of precedent chronic rhinosinusitis with risk of non–cystic fibrosis bronchiectasis
22. Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps
23. Studies on activation and regulation of the coagulation cascade in chronic rhinosinusitis with nasal polyps
24. Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS ‐24 and SINUS ‐52 trials
25. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
26. Use of intraoperative frontal sinus mometasone‐eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polyps
27. Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: A randomized controlled clinical trial
28. Elevation of activated neutrophils in chronic rhinosinusitis with nasal polyps
29. Anti‐phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps
30. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions
31. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies
32. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
33. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis
34. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol
35. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
36. Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer Cells
37. Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis
38. Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis
39. Prevalence of Bronchiectasis in Patients with Chronic Rhinosinusitis in a Tertiary Care Center
40. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps
41. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps
42. Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis
43. Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease
44. Targeted Molecular Therapies in Allergy and Rhinology
45. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps
46. Decreased nasal polyp eosinophils but increased mast cells in a patient with aspirin-exacerbated respiratory disease treated with reslizumab
47. Reply to “Nasal cromolyn in the treatment of rhinitis”
48. Integrin β6 microparticles in nasal lavage fluids; potential new biomarkers for basal cell activation in chronic rhinosinusitis
49. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19
50. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health–sponsored workshop
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.